PANC » Topics » ITEM 8.01 OTHER EVENTS.

This excerpt taken from the PANC 8-K filed Sep 18, 2008.

ITEM 8.01 OTHER EVENTS.

Panacos Pharmaceuticals, Inc. submitted a series of questions regarding bevirimat, its lead compound in development for HIV, to the U.S. Food and Drug Administration in the third quarter of 2008. The Agency’s response included a request to review the efficacy, safety, and pharmacokinetic data from Panacos’ ongoing multinational study of bevirimat’s tablets dosed twice daily (Study 204) prior to providing final guidance on the design of the bevirimat extended-duration trial in treatment-experienced patients (Study 205). Therefore, Panacos now expects to begin enrolling patients in Study 205 during the first half of 2009.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PANACOS PHARMACEUTICALS, INC.
Dated: September 18, 2008     By:   /S/ Alan W. Dunton
       

Alan W. Dunton, M.D.

President and Chief Executive Officer

This excerpt taken from the PANC 8-K filed Jun 17, 2008.

ITEM 8.01 OTHER EVENTS.

On June 17, 2008, Panacos Pharmaceuticals, Inc. issued a press release announcing the results of a Phase 2b prospective study of bevirimat, which confirm the recently discovered factors that predict patient response to bevirimat. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

This excerpt taken from the PANC 8-K filed Mar 4, 2008.

ITEM 8.01 OTHER EVENTS

On March 4, 2008, the Company also announced final results of the Phase 2b dose escalation study of bevirimat. A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

This excerpt taken from the PANC 8-K filed Jun 20, 2007.

ITEM 8.01 OTHER EVENTS

On June 20, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) issued a press release announcing preliminary results from the 250 mg cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resistance. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

This excerpt taken from the PANC 8-K filed Jun 14, 2007.

ITEM 8.01 OTHER EVENTS

The Board instated a new Statement of Policy with respect to Equity Award Approvals. A copy of the Statement of Policy with respect to Equity Award Approvals is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

This excerpt taken from the PANC 8-K filed May 2, 2007.

ITEM 8.01 OTHER EVENTS

Also in the press release dated May 2, 2007, Panacos provided an update on the status of its Phase 2b dose escalation study of bevirimat.

A copy of the press release is filed herewith as Exhibit 99.1. Solely the information contained therein updating the status of its Phase 2b dose escalation study of bevirimat is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

This excerpt taken from the PANC 8-K filed Mar 12, 2007.

ITEM 8.01 OTHER EVENTS

On March 12, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) issued a press release announcing its bevirimat phase 2b dose escalation strategy and additional information regarding the next phase 2b cohort. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

This excerpt taken from the PANC 8-K filed Feb 21, 2007.

ITEM 8.01 OTHER EVENTS

Also in our press release dated February 21, 2007, we provided an update on the status of the first bevirimat Phase 2b cohort. A copy of the press release is filed herewith as Exhibit 99.1. Solely the information contained therein updating the status of the first bevirimat Phase 2b cohort is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

This excerpt taken from the PANC 8-K filed Dec 19, 2006.

ITEM 8.01 OTHER EVENTS

On December 19, 2006, Panacos Pharmaceuticals, Inc. (the “Company”) announced first cohort results for its Phase 2b clinical trial of bevirimat (previously designated PA-457), the Company’s lead drug candidate for the treatment of HIV. The press release regarding this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

This excerpt taken from the PANC 8-K filed Mar 23, 2006.

ITEM 8.01 OTHER EVENTS

On March 23, 2006, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that it will present at the BioCentury Future Leaders Conference to be held at Millennium Broadway Hotel & Conference Center in New York, NY on March 30, 2006. Dr. Samuel Ackerman, Panacos’ President and CEO, will give a corporate overview and clinical update at 2:00 p.m. EST.

This excerpt taken from the PANC 8-K filed Feb 27, 2006.

ITEM 8.01 OTHER EVENTS

On February 27, 2006, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that it will present and provide a development update at the Cowen & Co. 26th Annual Health Care Conference to be held at The Marriott Copley Place in Boston, MA from March 6-9, 2006.

This excerpt taken from the PANC 8-K filed Nov 21, 2005.

ITEM 8.01 OTHER EVENTS.

 

Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announces that the Company will recognize a non-cash stock compensation charge in the fourth quarter of 2005 of $2.4 million in addition to its losses previously forecast. The additional non-cash compensation charge arises primarily from the recognition, connected with an employee’s resignation, of potential stock compensation charges that arose as a result of the acceleration of option vesting in connection with the merger between V. I. Technologies, Inc. and Panacos completed on March 11, 2005. Carl Wild, Ph.D., the Company’s co-founder and Chief Science Officer, is resigning from the Company to pursue other interests, effective November 25, 2005. Dr. Wild will continue to serve as a consultant to the Company for approximately three months following his resignation. As a result of the additional anticipated charge, the Company is revising its guidance for net income in the fourth quarter of 2005 to a net loss of between $9.4 million and $10.1 million from its previous guidance of $7.0 million to $7.75 million. The Company believes that its cash, cash equivalents and marketable securities balance as of December 31, 2005 is likely to be in the range of $86 million to $87 million.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

PANACOS PHARMACEUTICALS, INC.

 

Dated: November 21, 2005

 

By: /s/ Peyton J. Marshall

Peyton J. Marshall, Ph.D.

Executive Vice President and Chief Financial Officer

This excerpt taken from the PANC 8-K filed Sep 28, 2005.

ITEM 8.01    OTHER EVENTS.

 

On September 28, 2005, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that it has filed a preliminary prospectus supplement to its two shelf Registration Statements on Form S-3 (Registration Nos. 333-124894 and 333-128135) with the Securities and Exchange Commission relating to a proposed underwritten public offering of eight million shares of its common stock. It is currently anticipated that the underwriters will be granted an over-allotment option for an additional 1.2 million shares of common stock. All of the shares are being sold by Panacos. SG Cowen & Co., LLC and Bear, Stearns & Co. Inc. are acting as joint book runners for the offering. Acting as co-managers for the offering are Needham & Company, LLC and Leerink Swann & Company.

 

ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits.

 

Exhibit No.

  

Exhibit


99.1    Press Release of Panacos Pharmaceuticals, Inc. dated September 28, 2005.

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PANACOS PHARMACEUTICALS, INC.

 

Dated: September 28, 2005

 

 

By: /s/ Peyton J. Marshall

Peyton J. Marshall, Ph.D.

Executive Vice President and Chief Financial Officer


EXHIBIT INDEX

 

 

 

Exhibit No.

  

Exhibit


99.1    Press Release of Panacos Pharmaceuticals, Inc. dated September 28, 2005.
This excerpt taken from the PANC 8-K filed Aug 23, 2005.

ITEM 8.01 OTHER EVENTS

 

On August 22, 2005, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that it had successfully completed the Phase 2a clinical study of its lead HIV drug candidate, PA-457, and provided preliminary analysis of the results. The study met its primary endpoint by demonstrating a statistically significant reduction in the level of HIV in the blood, known as viral load, compared to placebo. The median reduction in viral load in the trial was greater than 1 log10, or a 90% decrease, at the highest dose. PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors, with broad activity against HIV, including strains resistant to currently approved drugs, the most common cause of HIV treatment failure.

 

This excerpt taken from the PANC 8-K filed Aug 18, 2005.

ITEM 8.01 OTHER EVENTS.

 

On August 15, 2005, stockholders of V.I. Technologies, Inc. (“Vitex”) approved an amendment to Vitex’s Restated Certificate of Incorporation to change the corporate name from V.I. Technologies, Inc. to Panacos Pharmaceuticals, Inc. Vitex amended its Restated Certificate of Incorporation on August 15, 2005. The name change became effective on August 17, 2005.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits.

 

Exhibit
No.


  

Exhibit


99.1    Press Release of Panacos Pharmaceuticals, Inc. dated August 18, 2005 regarding change of corporate name.
99.2    Press Release of Panacos Pharmaceuticals, Inc. dated August 18, 2005 regarding appointment of Executive Vice President and Chief Financial Officer.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        V. I. TECHNOLOGIES, INC.
Dated: August 18, 2005       By:  

/s/ Samuel K. Ackerman


           

Samuel K. Ackerman, M.D.

President and Chief Executive Officer

 

 


EXHIBIT INDEX

 

Exhibit
No.


  

Exhibit


99.1    Press Release of Panacos Pharmaceuticals, Inc. dated August 18, 2005 regarding change of corporate name.
99.2    Press Release of Panacos Pharmaceuticals, Inc. dated August 18, 2005 regarding appointment of Executive Vice President and Chief Financial Officer.
This excerpt taken from the PANC 8-K filed Jul 7, 2005.

ITEM 8.01 OTHER EVENTS

 

On June 30, 2005, V.I. Technologies, Inc. (“Vitex” or the “Company”) provided a corporate update, including the status of key clinical and development programs and announced its plans to discontinue direct investment in the development of the INACTINE system for red blood cells while undertaking efforts to license the technology and intellectual property to potential partners. It also announced its intention to seek shareholder approval to change the corporate name to Panacos Pharmaceuticals. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

This excerpt taken from the PANC 8-K filed Jun 30, 2005.

ITEM 8.01 OTHER EVENTS

 

On June 30, 2005, V.I. Technologies, Inc. (“Vitex” or the “Company”) provided a corporate update, including the status of key clinical and development programs and announced its plans to discontinue direct investment in the development of the INACTINE system for red blood cells while undertaking efforts to license the technology and intellectual property to potential partners. It also announced its intention to seek shareholder approval to change the corporate name to Panacos Pharmaceuticals. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

This excerpt taken from the PANC 8-K filed Mar 31, 2005.

ITEM 8.01 OTHER EVENTS

 

On March 30, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) announced that it has received formal notification from The Nasdaq Stock Market, Inc. (“Nasdaq”) that the Company has regained compliance with the minimum bid and shareholder equity requirements for continued listing on the Nasdaq National Market. This brings the Company into full compliance with these requirements for continued listing. There are no further actions required of the Company.

 

This excerpt taken from the PANC 8-K filed Mar 16, 2005.

ITEM 8.01 OTHER EVENTS

 

On March 14, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) announced that the Board of Directors of Vitex has approved a reverse split of the Company’s common stock.

 

As previously announced, the Board had been authorized by Vitex shareholders at a special shareholders meeting held on March 10, 2005 to effect a reverse split of the common stock in the range of 1:5 to 1:20. Pursuant to this authorization, the Board approved a 1-for-10 reverse split of the Company’s common stock. Shares held as of the close of business on March 14, 2005 have been split, and shares began trading on a post-split basis on March 15, 2005. Vitex has approximately 38.2 million shares outstanding after the 1-for-10 reverse split.

 

This excerpt taken from the PANC 8-K filed Mar 10, 2005.

ITEM 8.01 OTHER EVENTS

 

On March 10, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) announced that shareholders of both Vitex and Panacos approved the merger between the two companies in separate special shareholder meetings.

 

The Vitex shareholders also approved all other resolutions related to the merger contained in the Joint Proxy Statement/Prospectus, including the issuance of shares and warrants as part of a $20 million private placement transaction led by Great Point Partners. Under the terms of the merger, Vitex will issue approximately 227.5 million shares to acquire all outstanding shares of Panacos. The merger and financing are expected to close shortly.

 

This excerpt taken from the PANC 8-K filed Mar 9, 2005.

ITEM 8.01 OTHER EVENTS

 

On March 9, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) announced the filing of a registration statement for a proposed rights offering of its common stock with a maximum value of approximately $5.5 million through the distribution of subscription rights to all of its shareholders of record as of March 9. Under the terms of the rights offering, record date shareholders will receive 0.8 subscription rights for each share of common stock which they own as of the record date, thereby entitling them collectively to purchase up to a maximum of 27.5 million shares of Vitex stock. The exercise price will be $0.20 per share, the same pricing as in the $20 million private placement announced in December, which also included warrants and which is expected to close concurrently with the Company’s merger with Panacos Pharmaceuticals. The rights offering is also conditioned on the closing of the merger with Panacos Pharmaceuticals.

 

This excerpt taken from the PANC 8-K filed Mar 7, 2005.

ITEM 8.01 OTHER EVENTS

 

On March 7, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) announced, pursuant to rules of the Nasdaq Stock Market that became effective in 2004, that it received a going concern qualification in the audit report which was included in its Form 10-K recently filed with the Securities and Exchange Commission. The qualification was based on the cash balance of the Company as of December 31, 2004, which was not sufficient to fund operations over the next year, as previously disclosed by the Company.

 

In December 2004, Vitex announced that it had signed binding agreements with a group of investors led by Great Point Partners for a $20 million private placement of common stock and warrants to purchase common stock. The financing is subject to shareholder approval and to closing Vitex’s proposed merger with Panacos Pharmaceuticals. Vitex’s stockholders meeting to vote on the Great Point Partners financing and the merger with Panacos Pharmaceuticals is scheduled for March 10.

 

This excerpt taken from the PANC 8-K filed Feb 22, 2005.

ITEM 8.01 OTHER EVENTS

 

On February 22, 2005, V.I. Technologies, Inc. (“Vitex” or “the Company”) reported that the Nasdaq Stock Market, Inc. has granted the Company an extension until March 15, 2005 to comply with the $10,000,000 minimum stockholders’ equity requirement for continued listing on the Nasdaq National Market set forth in Nasdaq Marketplace Rule 4450(a)(3).

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki